Kathryn G Roberts

List of Publications by Year
in descending order

107 papers	9,531 citations	71102 41 h-index	39675 94 g-index
109 all docs	109 docs citations	109 times ranked	9060 citing authors

#	Article	IF	Citations
1	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	7.1	35
2	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
3	Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood, 2022, 139, 3519-3531.	1.4	20
4	CDX2 and IDH1/2: new potential players in ALL. Blood, 2022, 139, 1778-1779.	1.4	0
5	ZNF384 Fusion Oncoproteins Drive Lineage Aberrancy in Acute Leukemia. Blood Cancer Discovery, 2022, 3, 240-263.	5.0	11
6	Acute Leukemia Classification Using Transcriptional Profiles From Low-Cost Nanopore mRNA Sequencing. JCO Precision Oncology, 2022, 6, e2100326.	3.0	2
7	Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nature Cancer, 2022, 3, 768-782.	13.2	15
8	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Advances, 2022, 6, 3386-3397.	5.2	8
9	SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood, 2021, 137, 1835-1838.	1.4	6
10	<i>GATA3</i> rs3824662A allele in Bâ€cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with <i>CRLF2</i> rearrangement and poor prognosis. American Journal of Hematology, 2021, 96, E71-E74.	4.1	5
11	The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics. Molecular Cancer Research, 2021, 19, 636-650.	3.4	8
12	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood, 2021, 137, 471-484.	1.4	70
13	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	13.2	70
14	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematology,the, 2021, 8, e55-e66.	4.6	32
15	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discovery, 2021, 11, 1440-1453.	9.4	137
16	The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment. Haematologica, 2021, 106, 2242-2245.	3.5	3
17	Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan. Scientific Reports, 2021, 11, 5802.	3.3	4
18	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71

#	Article	IF	Citations
19	Molecular classification improves risk assessment in adult <i>BCR-ABL1â€“</i>negative B-ALL. Blood, 2021, 138, 948-958.	1.4	59
20	Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia. Genes, 2021, 12, 687.	2.4	11
21	Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83
22	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0
23	The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood, 2021, 138, 1870-1884.	1.4	20
24	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. Blood, 2021, 138, 2382-2382.	1.4	0
25	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3476-3476.	1.4	0
26	Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3304-3304.	1.4	0
27	Interleukin-7 receptor Î± mutational activation can initiate precursor B-cell acute lymphoblastic leukemia. Nature Communications, 2021, 12, 7268.	12.8	24
28	The Biology of B-Progenitor Acute Lymphoblastic Leukemia. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a034835.	6.2	40
29	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533.	4.6	43
30	At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. British Journal of Haematology, 2020, 191, 37-43.	2.5	9
31	Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2020, 37, 867-882.e12.	16.8	108
32	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
33	Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2020, 1, 96-111.	5.0	93
34	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
35	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2020, 136, 12-13.	1.4	2
36	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1

#	Article	IF	Citations
37	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. Blood, 2020, 136, 39-40.	1.4	2
38	OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clinical Cancer Research, 2019, 25, 4493-4503.	7.0	30
39	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
40	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44
41	Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 1641-1641.	1.4	11
42	Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.. Journal of Clinical Oncology, 2019, 37, 7023-7023.	1.6	1
43	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 2577-2577.	1.4	3
44	The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression. Blood, 2019, 134, 2748-2748.	1.4	0
45	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
46	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget, 2018, 9, 8027-8041.	1.8	42
47	Why and how to treat Ph-like ALL?. Best Practice and Research in Clinical Haematology, 2018, 31, 351-356.	1.7	29
48	Genetics and prognosis of ALL in children vs adults. Hematology American Society of Hematology Education Program, 2018, 2018, 137-145.	2.5	90
49	TKI resistance in Ph-like ALL. Blood, 2018, 131, 2181-2182.	1.4	1
50	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97
51	ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood, 2018, 132, 861-865.	1.4	53
52	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. Blood, 2018, 132, 1552-1552.	1.4	3
53	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14
54	Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome. Journal of Experimental Medicine, 2017, 214, 773-791.	8.5	27

#	Article	IF	Citations
55	High Frequency and Poor Outcome of Philadelphia Chromosomeâ€“Like Acute Lymphoblastic Leukemia in Adults. Journal of Clinical Oncology, 2017, 35, 394-401.	1.6	326
56	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
57	CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients. American Journal of Clinical Pathology, 2017, 147, 357-363.	0.7	51
58	Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581.	1.4	285
59	Adults with Philadelphia chromosomeâ€“like acute lymphoblastic leukemia frequently have <i>IGH-CRLF2</i> and <i>JAK2</i> mutations, persistence of minimal residual disease and poor prognosis. Haematologica, 2017, 102, 130-138.	3.5	136
60	Philadelphia Chromosomeâ€“like Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 464-470.	0.4	84
61	Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica, 2017, 102, e514-e517.	3.5	13
62	The biology of Philadelphia chromosome-like ALL. Best Practice and Research in Clinical Haematology, 2017, 30, 212-221.	1.7	38
63	Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Advances, 2017, 1, 2361-2374.	5.2	11
64	Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Advances, 2017, 1, 1657-1671.	5.2	76
65	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood, 2016, 127, 3004-3014.	1.4	244
66	Characterization of leukemias with ETV6-ABL1 fusion. Haematologica, 2016, 101, 1082-1093.	3.5	66
67	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218
68	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	21.4	231
69	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	16.8	118
70	High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy. Blood, 2016, 128, 1082-1082.	1.4	2
71	Genetic Modeling and Therapeutic Targeting of ETV6-NTRK3 with Loxo-101in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 278-278.	1.4	3
72	The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003. Blood, 2016, 128, 2914-2914.	1.4	4

#	Article	IF	Citations
73	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. Blood, 2016, 128, 451-451.	1.4	4
74	Clinical Implementation of a Testing Algorithm for the Diagnosis of Ph-like B-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2915-2915.	1.4	0
75	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	1.4	76
76	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
77	PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood, 2015, 125, 3609-3617.	1.4	72
78	Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2015, 14, 364-374.	4.1	49
79	Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nature Reviews Clinical Oncology, 2015, 12, 344-357.	27.6	243
80	CONSERTING: integrating copy-number analysis with structural-variation detection. Nature Methods, 2015, 12, 527-530.	19.0	68
81	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 343-356.	16.8	145
82	Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1423-1423.	1.4	1
83	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2529-2529.	1.4	3
84	High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. Blood, 2015, 126, 2618-2618.	1.4	5
85	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	1.4	1
86	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2015, 126, 694-694.	1.4	2
87	Characterization of Leukemias with ETV6-ABL1 Fusion. Blood, 2015, 126, 84-84.	1.4	1
88	Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 692-692.	1.4	3
89	Outcomes of Children With <i>BCR-ABL1</i>â€“Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology, 2014, 32, 3012-3020.	1.6	223
90	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161

#	Article	IF	Citations
91	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 786-786.	1.4	3
92	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	1.4	1
93	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 128-128.	1.4	0
94	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
95	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood, 2013, 121, 485-488.	1.4	156
96	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264
97	Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory <i>EBF1-PDGFRB</i>â€“Positive Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, e413-e416.	1.6	202
98	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 232-232.	1.4	8
99	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. Blood, 2013, 122, 825-825.	1.4	8
100	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	1.4	65
101	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood, 2012, 120, 3510-3518.	1.4	263
102	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	16.8	621
103	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	27.8	1,430
104	How new advances in genetic analysis are influencing the understanding and treatment of childhood acute leukemia. Current Opinion in Pediatrics, 2011, 23, 34-40.	2.0	23
105	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. Blood, 2011, 118, 743-743.	1.4	3
106	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. Blood, 2011, 118, 67-67.	1.4	0
107	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 68-68.	1.4	0